Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) insider Joseph P. Lyssikatos sold 2,707 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $27.61, for a total value of $74,740.27. Following the sale, the insider now owns 1,067,180 shares of the company’s stock, valued at $29,464,839.80. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Enliven Therapeutics Price Performance
Shares of ELVN stock opened at $26.97 on Friday. The business’s fifty day moving average price is $23.34 and its 200 day moving average price is $22.22. Enliven Therapeutics, Inc. has a 1-year low of $9.80 and a 1-year high of $28.62. The firm has a market capitalization of $1.27 billion, a PE ratio of -13.97 and a beta of 1.10.
Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.17. Equities research analysts expect that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Get Our Latest Report on Enliven Therapeutics
Institutional Trading of Enliven Therapeutics
Large investors have recently bought and sold shares of the company. Quest Partners LLC grew its holdings in Enliven Therapeutics by 87.3% in the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock valued at $37,000 after purchasing an additional 742 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Enliven Therapeutics by 67.0% in the first quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock valued at $140,000 after purchasing an additional 3,189 shares during the last quarter. EntryPoint Capital LLC acquired a new stake in Enliven Therapeutics in the first quarter valued at $167,000. SG Americas Securities LLC acquired a new stake in Enliven Therapeutics in the third quarter valued at $256,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Enliven Therapeutics in the second quarter valued at $322,000. Institutional investors and hedge funds own 95.08% of the company’s stock.
Enliven Therapeutics Company Profile
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Read More
- Five stocks we like better than Enliven Therapeutics
- There Are Different Types of Stock To Invest In
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- What is a Dividend King?
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- 3 Small Caps With Big Return Potential
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.